> **Komzifti**
> Bangladesh · access guide

Komzifti in Bangladesh

Komzifti - overview

Komzifti (ziftomenib) is manufactured by Kura Oncology and indicated for R/R NPM1-mutant acute myeloid leukemia (AML). It is an oral small molecule approved by the US FDA in 2025 and may be accessible to patients in Bangladesh through a Named Patient Program or personal-import pathway.

Access in Bangladesh

Bangladesh's DGDA accepts named-patient import under personal-use exceptions; volume is lower but pathway exists.

How Reserve Meds coordinates access in Bangladesh

1. Patient or treating physician submits a request.
2. We verify clinical appropriateness and Bangladesh-specific eligibility.
3. Treating physician in Bangladesh issues prescription and clinical justification.
4. Country-specific NPP/personal-import forms are prepared and filed.
5. We source Komzifti from a DSCSA-compliant US specialty wholesaler.
6. Cold-chain shipment to the patient's physician or hospital pharmacy in Bangladesh.

Typical timeline for Bangladesh

End-to-end, most requests are completed in 2-6 weeks. Bangladesh's tier 3 regulatory maturity typically supports longer processing times.

What patients and physicians in Bangladesh ask

- Is the pathway legal in Bangladesh? **Yes** - it operates under Bangladesh's established NPP or personal-import framework.
- Does my insurance cover it? **Typically no** for NPP drugs; patient prepayment is standard.
- What physician credentials do I need? **A licensed physician in Bangladesh** able to issue the prescription and clinical justification.
- What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
- Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.

Start a request for Komzifti in Bangladesh

Start your case Or message us on WhatsApp

About Komzifti

Oncology (Leukemia)
Manufacturer: Kura Oncology
Modality:
Full drug page ->

About Bangladesh

South Asia
Tier 3
Full country page ->

See also

Access pathways
Articles & guides
Clinical resource (HCP)

YELLOW AI Regulatory Review Agent, preliminary signal Biologic drug requires DGDA import confirmation for the specific patient indication. Cold-chain shipping validated. Typically 2-4 week approval. Rule: biologic_moh_confirmation • Reviewed 2026-04-22
Start your case Or message us on WhatsApp

Reserve Meds's role

US-based concierge coordinator for cross-border specialty medicine. We are not the prescriber, not the dispensing pharmacy, and not the manufacturer. All clinical decisions remain with your treating physician.